10-Q: bioAffinity Technologies Reports Increased Revenue but Continues to Face Going Concern Challenges in Q3 2024

bioAffinity Technologies saw a significant increase in revenue in Q3 2024, primarily due to the acquisition of a clinical pathology lab, but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.

Summary

• bioAffinity Technologies reported a net loss of $2.0 million for the three months ended September 30, 2024, compared to a net loss of $2.3 million for the same period in 2023.
• The company's net revenue for the three months ended September 30, 2024, was $2.35 million, a significant increase from $298,484 in the same period of 2023, primarily due to the acquisition of Precision Pathology Laboratory Services (PPLS).
• Operating expenses for the quarter totaled $4.3 million, up from $2.6 million in 2023, driven by increased direct costs and depreciation related to the acquired laboratory.
• For the nine months ended September 30, 2024, the net loss was $6.1 million, compared to $5.6 million in 2023.
• Net revenue for the nine months ended September 30, 2024, was $7.15 million, a substantial increase from $319,143 in the same period of 2023.
• The company's operating expenses for the nine months ended September 30, 2024, were $13.2 million, compared to $5.9 million in 2023.
• bioAffinity Technologies had cash and cash equivalents of $0.8 million as of September 30, 2024, and management has expressed substantial doubt about the company's ability to continue as a going concern for at least twelve months.
• The company raised an additional $2.3 million in cash through a registered direct offering and concurrent private placement on October 21, 2024, but expects this will only support operations until March 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's significant revenue growth due to the PPLS acquisition and positive developments like the Japanese patent and Federal Supply Schedule inclusion, the company's substantial losses, weak cash position, and going concern warning raise serious concerns about its financial viability. The need for further capital raises and the uncertainty surrounding future profitability contribute to a negative sentiment.

Positives

• The acquisition of PPLS has led to a substantial increase in revenue, with patient service fees being the primary driver.
• The company has secured a Japanese patent for the method used by its CyPath Lung diagnostic test.
• A peer-reviewed study suggests that CyPath Lung could lead to significant cost savings in healthcare.
• CyPath Lung has been added to the U.S. Federal Supply Schedule, potentially opening up a new revenue stream through the Veterans Health Administration.
• The company has appointed a new Chief Science Officer and a new Chief Financial Officer.

Negatives

• The company continues to operate at a loss, with a net loss of $6.1 million for the nine months ended September 30, 2024.
• Operating expenses have increased significantly due to the acquisition of PPLS.
• The company has a substantial accumulated deficit of $50.7 million as of September 30, 2024.
• There is substantial doubt about the company's ability to continue as a going concern for at least twelve months.
• The company's cash and cash equivalents were only $0.8 million as of September 30, 2024, and are expected to last only until March 2025.

Risks

• The company's business plan relies on its ability to obtain additional capital and financing.
• The company may be required to cease operations if it cannot raise sufficient capital.
• The company is in the preliminary phases of developing and commercializing its diagnostic tests and therapeutic products.
• The company may not be able to obtain regulatory approvals for its diagnostic tests and therapeutic products.
• The company may not be able to generate sufficient income to achieve profitability.
• The company's failure to file a registration statement for shares issued in October 2024 or to hold a timely shareholder meeting could result in a breach of agreements.
• Management's substantial ownership could prevent investors from affecting company matters.

Future Outlook

The company expects to continue to incur significant operating losses for the foreseeable future as it continues the development of its diagnostic tests and advances them through clinical trials. The company anticipates raising additional cash through the sale of equity or debt securities, collaborative arrangements, or a combination thereof to continue to fund its operations. Management believes that current cash and anticipated revenue will not be sufficient to support operations beyond March 2025.

Management Comments

• Management concludes that there is substantial doubt about the company's ability to continue as a going concern for a period of at least twelve months.
• Management believes that current cash and anticipated revenue from operations will not be sufficient to support operations beyond March 2025.
• Management is seeking sources of financing to fund continued operations and research and development programs.

Industry Context

The company operates in the competitive diagnostic and therapeutic biotechnology industry, focusing on early cancer detection and treatment. The acquisition of PPLS and the addition of CyPath Lung to the Federal Supply Schedule are strategic moves to increase revenue and market access. The company's financial challenges highlight the high costs and risks associated with developing and commercializing new medical technologies.

Comparison to Industry Standards

• bioAffinity's revenue growth is notable compared to other early-stage biotech companies, primarily due to the acquisition of a revenue-generating laboratory.
• However, the company's continued losses and going concern warning are not uncommon for companies in this sector, which often require significant capital investment and have long development timelines.
• Compared to companies like Exact Sciences (EXAS) or Guardant Health (GH), which have established commercial diagnostic products, bioAffinity is still in an earlier stage of commercialization.
• The company's reliance on external funding is similar to many other biotech startups, but the current cash position and going concern warning are concerning.
• The company's focus on non-invasive diagnostics aligns with a growing trend in the industry, but the success of CyPath Lung will depend on clinical validation and market adoption.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various disputes and litigation matters that arise in the ordinary course of business.
• To date, the company has no material pending legal proceedings.

Related Party Transactions

• The royalty income from CyPath Lung and clinical flow cytometry services income, beginning September 19, 2023, are related party income and, therefore, eliminated from consolidated net revenues.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company cannot secure additional funding and achieve profitability.
• Employees may be impacted by potential layoffs or restructuring if the company's financial situation does not improve.
• Customers may be affected by potential disruptions in service if the company faces financial difficulties.
• Suppliers and creditors may face the risk of non-payment if the company's financial situation deteriorates.

Next Steps

• The company needs to secure additional funding to continue operations beyond March 2025.
• The company needs to continue to develop and commercialize its diagnostic tests and therapeutic products.
• The company needs to obtain regulatory approvals for its diagnostic tests and therapeutic products.
• The company needs to expand commercialization of CyPath Lung.
• The company needs to file a resale registration statement for the shares issued in October 2024.
• The company needs to hold a stockholders meeting to obtain approval for the exercise of warrants issued in October 2024.

Key Dates

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer, diagnostic test, clinical pathology, revenue, operating expenses, net loss, going concern, capital raise, PPLS, warrants, stock options, research and development, laboratory services